These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 7383068)
1. Drugs of limited commercial value. Van Woert MH N Engl J Med; 1980 Jul; 303(2):114. PubMed ID: 7383068 [No Abstract] [Full Text] [Related]
2. Profitable and nonprofitable drugs. Van Woert MH N Engl J Med; 1978 Apr; 298(16):903-6. PubMed ID: 634333 [No Abstract] [Full Text] [Related]
3. Research regulation, and development of new pharmaceuticals: past, present, and future. 1. Lasagna L Am J Med Sci; 1972 Jan; 263(1):9-18. PubMed ID: 4257990 [No Abstract] [Full Text] [Related]
4. Therapeutic equivalency of drugs. Fact or fiction? Stetler CJ Med Ann Dist Columbia; 1969 Jun; 38(6):297-300. PubMed ID: 5257886 [No Abstract] [Full Text] [Related]
5. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
6. The Food and Drug Administration's requirements for approval of new dental drugs. Gilkes CC Symp Pharmacol Ther Toxicol Group; 1975 Apr; ():5-12. PubMed ID: 1064180 [No Abstract] [Full Text] [Related]
8. Veterinary drug availability. Gloyd J J Am Vet Med Assoc; 1980 Apr; 176(7):611-4. PubMed ID: 7372533 [No Abstract] [Full Text] [Related]
9. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
10. Development of orphan products. FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406 [No Abstract] [Full Text] [Related]
11. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
12. Prescription drug advertising--should states regulate what is false and misleading? Shaeffer J Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454 [No Abstract] [Full Text] [Related]
13. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
14. Pharmaceutical postmarket review: fact or fiction? Schanz SJ Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391 [No Abstract] [Full Text] [Related]
15. The learned intermediary doctrine: past, present and future. Alsobrook HB Leg Med; 1994; ():269-80. PubMed ID: 7830482 [No Abstract] [Full Text] [Related]
16. The development of orphan products. Finkel MJ N Engl J Med; 1982 Oct; 307(15):963-4. PubMed ID: 7110287 [No Abstract] [Full Text] [Related]
17. Drug product liability and health care delivery systems. Sage WM Stanford Law Rev; 1988 Apr; 40(4):989-1026. PubMed ID: 10318110 [No Abstract] [Full Text] [Related]
18. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
19. New drugs: the AMA and the FDA. Appel JZ Ann Allergy; 1966 Jul; 24(7):333-6. PubMed ID: 5941864 [No Abstract] [Full Text] [Related]
20. New drugs and the Kefauver-Harris amendment. Krantz JC J New Drugs; 1966; 6(2):77-9. PubMed ID: 5917906 [No Abstract] [Full Text] [Related] [Next] [New Search]